(Reuters) - Europe's drugs regulator said on Friday its safety panel found no evidence that Gilead's remdesivir caused kidney problems in some COVID-19 patients. Remdesivir, sold under the brand name ...

Feb 12 (Reuters) - A safety panel at the European Medicines Agency said on Friday there was no evidence that Gilead's GILD.O COVID-19 drug remdesivir caused kidney problems in some patients.

Gilead Sciences has posted data on 53 severe COVID-19 patients who received remdesivir on a compassionate use basis. More than two-thirds of the patients improved after receiving remdesivir, although ...

Two of the experimental coronavirus drugs, chloroquine, and hydroxychloroquine are a breeze to synthesize. But remdesivir, possibly the most promising candidate, is anything but. It's a royal pain.

Remdesivir offered a glimmer of hope in the fight against the coronavirus on April 29, 2020, when results of a promising clinical trial were released. After the trial revealed it could speed up ...

Two widows in the Inland Empire are suing Kaiser Permanente and Redlands Community Hospital for using Remdesivir to treat their husbands' COVID-19 diagnoses. "I am a widow and I am 52," said widow ...

A preliminary report on COVID-19 patients treated with the experimental drug remdesivir suggests that the antiviral medication may lower the risk of death in severely ill patients and improve the ...

Gilead Sciences Inc. said it is recalling tens of thousands of vials of its COVID-19 drug treatment remdesivir due to glass contamination, which it warned could lead to adverse health effects such as ...

Dr. Tony Reed, the chief medical officer at Temple University Hospital in Philadelphia, has seen remdesivir in action. The hospital system gave the drug to patients in trials to help figure out how ...

Some U.S. states facing a surge in coronavirus cases are now running low on remdesivir, the only drug approved to treat COVID-19, while other parts of the country have ample supplies of the ...